...
首页> 外文期刊>Cureus. >Autoimmune Hemolytic Anemia After Cyanocobalamin Replacement in a Patient With a Previous Diagnosis of Pernicious Anemia: A Case Report
【24h】

Autoimmune Hemolytic Anemia After Cyanocobalamin Replacement in a Patient With a Previous Diagnosis of Pernicious Anemia: A Case Report

机译:自身免疫性溶血性贫血后氰基胺替代患者在患者患者上诊断的可生性贫血:案例报告

获取原文
           

摘要

Pernicious anemia (PA) is associated with other autoimmune diseases, such as hypothyroidism, type 1 diabetes mellitus (DM1), Addison's disease, and vitiligo. The association between PA and autoimmune hemolytic anemia (AIHA) is rare, with less than 30 cases reported in the literature. In this paper, we report a case of a patient with a confirmed diagnosis of PA, who, six months after starting treatment with cyanocobalamin, presented with severe hemolysis with a positive direct antiglobulin test (DAT) for warm antibodies; the patient responded well to glucocorticoid treatment. AIHA in PA patients can be triggered by cyanocobalamin replacement due to the expression of membrane antigens by mature red blood cells entering into the peripheral circulation. This association should be considered because these patients, in addition to cyanocobalamin replacement, will require immunosuppressive treatment, usually with glucocorticoids.
机译:可怕的贫血(PA)与其他自身免疫性疾病有关,例如甲状腺功能亢进,1型糖尿病(DM1),Addison病和白癜风。 PA和自身免疫溶血性贫血(AIHA)之间的关联罕见,文献中报告了不到30例。在本文中,我们向患者报告了患者的患者,确诊为PA,六个月在用氰基胺开始治疗后六个月,呈现出严重的溶血性溶血溶解(DAT)用于温热抗体;患者对糖皮质激素治疗良好。 PA患者中的AIHA可以通过Cyanobalamin替代引发,由于进入外周循环的成熟红细胞的成熟红细胞表达膜抗原。应该考虑这种协会,因为这些患者除了氰基胺素替代外,通常需要免疫抑制治疗,通常是糖皮质激素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号